Regulus Therapeutics Inc. is a pre-clinical stage, biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. microRNAs are naturally occurring ribonucleic acid, molecules that play a critical role in regulating key biological pathways. It uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs. Its operations include acquiring and in-licensing rights, developing its microRNA, undertaking basic research around microRNA targets and conducting preclinical studies for its initial programs. In January 2014, it established Regulus microMarkers, a research and development division focused on identifying microRNAs as biomarkers of human disease, which is designed to support its therapeutic pipeline. Through its microRNA target identification and validation efforts it has developed technologies for microRNA profiling and analysis of human clinical samples such as tissue.